Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00677807 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

415

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Indacaterol
DRUG: Placebo

Sponsor

Novartis